THE EXPRESSION OF THE TP53 GENE IN VARIOUS CLASSES OF ACUTE MYELOID LEUKEMIA

: Investigation of the underlying mechanisms involved in disease pathogenesis can open new insights into therapeutic strategies for patients with acute myeloblastic leukemia. A genetic mutation in TP53 (Tumor Protein 53) gene is detected in most malignancies and considered a key element in the determination of treatment planning due to its prognostic value; however, there are insufficient data for the evaluation of the amount of p53 expression as the product of the TP53 gene especially in hematologic malignancies such as acute myeloid leukemia (AML). The aim of this study was to evaluate p53 expression deregulation, according to different subtypes of acute myeloid leukemia.